Blue Health Intelligence, a data analytics and software company, undertook an evaluation of almost 170,000 unique GLP-1 users for weight loss, notes less than half of those prescribed stay on the medication for 12 weeks or more. Younger adults were less likely to continue the drug, whereas those who were prescribed the medication by an endocrinologist or obesity medicine specialist were more likely to continue for longer. Indeed, this data states 30% of patients dropped out of treatment after the first four weeks, and 58% at 12 weeks. Those who dropped out are unlikely to achieve clinically meaningful weight loss. The likelihood of continuance was further exacerbated for those with health inequities or who lived in underserved health regions. The data comes from Blue Cross Blue Shield Association members participating in Plans that provided coverage of these products, from 2014 through to end of 2023. Razia Hashmi, vice president for clinical affairs at Blue Cross Blue Shield wants to ‘…paint a clearer picture of what makes somebody successful.’ The missing piece here is why the patients stopped – side effects, failure to achieve initial weight loss, stigma and discrimination, or coverage issues related to cost and access. My longtime friend, colleague and bariatric surgeon at Stanford University, Dr. Dan Azagury rightly states ‘…The goal is for patients to stay on this for a significant amount of time. Most likely… beyond 12 weeks.’ https://lnkd.in/ediQskQx
Rajesh Aggarwal MD PhD FRCS FACS’ Post
More Relevant Posts
-
The new generation of GLP-1 drugs has demonstrated the role of biology vs. behavior in treating obesity and associated comorbidities, including cardiovascular health, and has generated tremendous enthusiasm and demand among patients, resulting in a severe shortage of doctors specializing in obesity treatment. Astonishingly, more than half of these specialists are concentrated in just four states—New York, Pennsylvania, Massachusetts, and California. This creates a significant patient-specialist mismatch, given that these states have lower obesity rates. Digbi pioneered the use of Precision Biology in delivering telehealth care for #obesity and #digestivehealth, and we are enhancing access to care by collaborating with Obesity specialists in every 50 states. Doctors acknowledge that everyone responds differently to medicine and food. Our unique data and bioinformatics platform consolidates millions of diverse data points, including #genetics and #gutmicrobiome, to offer personalized treatment plans amplifying doctor's care for obesity that include intelligent use of drugs with a focus on #deprescription and #prevention. This improves patient outcomes and resonates with employers and health plans looking to provide the best care while reducing healthcare costs, particularly GLP-1-related drug costs. We thank our employer, health plan, and consultant partners who support us in our mission. WTW Lockton Aon Virgin Pulse Labcorp Health Transformation Alliance HUB International OneDigital Advanced Health Mercer LG Digital Health
Obesity specialists are scarce. Here’s how that’s starting to change
https://www.statnews.com
To view or add a comment, sign in
-
When you partner with us at Weight Loss Physicians, you're gaining access to board-certified expertise in obesity medicine. We provide a thorough, safety-first approach that includes comprehensive care for any obesity-linked health condition you might have. 👨⚕️ On Your First Appointment (In-person or Virtual) We'll take a detailed health history, assess any obesity-related health problems, and create personalized nutrition and physical activity plans for you. We can even discuss medication options if appropriate. 🔬 Potential Tests Depending on your needs, we recommend a range of diagnostic tests like blood glucose levels, lipid levels, or even hormone assessments. 📋 Your Custom Treatment Plan Based on your unique medical needs and personal preferences, we will develop a treatment plan for you. Expect regular follow-ups to adjust your treatment as necessary and offer ongoing support. Choose Weight Loss Physicians for a holistic, evidence-based approach to sustainable wellness. https://lnkd.in/enYENRSB
Our Weight Loss Programs | Weight Loss Physicians
https://weightlossphysicians.net
To view or add a comment, sign in
-
Certified Diabetes Care & Education Specialists, Clinical Exercise Physiologist, Board Certified Health & Wellness Coach
To stay up-to-date on all things cardiovascular, metabolic, and renal health, I can read the major published studies, position papers, guidelines, and standards... or I can take a few days and attend the annual CMHC meeting in Boston and hear from many of the key thought leaders in the field. While it can be a little heavy in the area of medication therapies, there is a greater emphasis on lifestyle modification and how to inform, engage, and activate your clients. How do you stay current with all the research?
To view or add a comment, sign in
-
-
Being able to participate more in social life and a better quality of life – these are some of the effects reported by dialysis patients treated on hemodiafiltration, as seen in the CONVINCE Study. When researchers initiated the CONVINCE Study, they aimed to quantify the benefits patients could receive from high-dose hemodiafiltration (HDF) compared to the standard treatment, hemodialysis. The results were not only promising regarding HDF as a treatment method for reducing mortality rates, but they also highlighted the unique role that patient-reported outcomes (PROs) can play in medical studies for people with kidney disease and others. Krister Cromm, Fresenius Medical Care’s Director of Person-Centered Outcomes Research, played a critical role in gathering and analyzing data from the CONVINCE Study. According to Cromm, PROs provide valuable insights into how someone feels living with a chronic disease, leading to meaningful conversations about optimizing care and choosing the right treatment. “The CONVINCE study showed that it’s possible to achieve a higher quality of life and live longer with hemodiafiltration. For example, the study showed higher social participation, better physical function, better cognitive function and lower pain interference of participants. These are very promising prospects and a light at the end of the tunnel for many patients.” Read the full article to learn how these findings are shaping patient-centered care and improving outcomes in kidney health: https://lnkd.in/degPSfgE #ProudtobeFME #TogetherAhead #Healthcare #Dialysis
To view or add a comment, sign in
-
-
Co-Founder & Chief Medical Officer at Accomplish Health | Healthcare Futurist | Clinical Assistant Professor of Medicine - OUHSC
Entities with major COIs are attempting to gaslight the general public about obesity meds. They claim only 10-40% of people remain on obesity meds at 1 yr because of a lack of efficacy & side effects. Any clinician familiar with these meds can tell you these are NOT the primary issues. For example, med discontinuation rates in major clinical trials are only ~4-5%. Our in-house data suggests it's <1% with tailored prescribing. As for efficacy, we use a range of meds at Accomplish Health and average >22% weight reduction at 1 year—excellent results. See…if you talk with any experts, they will tell you the major issues preventing a higher level of med adherence are cost and drug access. So, it’s pretty ironic that PBMs (the gatekeepers of drug access and cost) are promoting studies that suggest an alternative explanation. If you believe anything a PBM tells you at this point, then I’ve got a bridge to sell you… Studies: [1] https://t.co/b7HQ38thTk [2] https://lnkd.in/gTtAdZ4c
The Societal Value of Broader Access to Antiobesity Medications
ncbi.nlm.nih.gov
To view or add a comment, sign in
-
Controlling Hypertension Through Education and Coaching in Kidney Disease (CHECK-D) NCT04087798 GO BLUE! Working with leading researchers at the @University of Michigan, eligible patients enrolled from the intervention group clinics will be given an Intervention-EDI which has personalized information about kidney disease. There will be space on this for the provider to type in any goals or key points they want the patient to remember. Additionally, patients in this group will also receive health coaching. Health coaches will conduct a baseline call and 4-6 coaching calls, based on patient's needs, over an 11-month period. There are 4 topic areas related to blood pressure and CKD that will be the focus of the calls. Coaches will also have pre-determined and vetted educational resources to provide patients if needed. Additionally, patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only). The MMAS-8 will be utilized by these coaches. This scale is to quantify adherence to pharmacological treatments by 8 items. Levels of adherence are based on the following scores: <6 = low adherence; 6-<8 = medium adherence; 8 = high adherence. #medicationadherence #patientreportedoutcomes #clinicaltrials #clinicalresearch #mmas8
To view or add a comment, sign in
-
-
#contingencymanagement #chronicdisease #drugcosts #behavioraleconomics While healthcare costs and BMI continue to rise, we should recall this old (c.2020) data: contingency management is effective, when the incentives are maintained. It's exciting to see innovators such as wellth nudging the field forward. https://lnkd.in/eWB3WcXR
Contingency management for individuals with chronic health conditions: A systematic review and meta-analysis of randomized controlled trials
sciencedirect.com
To view or add a comment, sign in
-
A new study by Mark Fendrick et al. explores more affordable obesity care with GLP-1, and here are our takeaways: 💸 Switching to cheaper weight maintenance programs after initial weight loss with expensive medications like GLP-1 can reduce lifetime healthcare spending. 🏋️ These cheaper programs might not be as powerful as full-dose GLP-1 treatments, but they still help keep the weight off and improve heart health. 👥 This approach makes sure that more people can benefit from initial weight loss treatments without spending too much. The study shows that cheaper weight maintenance programs save money but give fewer health benefits. This makes us ask: should we sacrifice efficacy for affordability, or try to make GLP-1 more affordable? It's also crucial to tailor these alternative programs to each person since everyone responds differently to weight loss treatments. Plus, we should focus on building lasting healthy habits for long-term health, reduced medication reliance and better obesity management. Read more: https://lnkd.in/gUjKMuVu #Obesity #ObesityManagement #Innovation #WeightLoss #AntiObesityMedications #HealthEquity #ComprehensiveCare #LongTermHealth #ObesityProgram #GLP1 #Wegovy #Ozempic #Victoza #Saxenda #Mounjaro #Diabetes #Cardiology #Heart #HeartHealth #Lifestyle #Weight #ObesityCare Oxford University Press University of Oxford #Healthcare
Balancing Innovation and Affordability in Anti-Obesity Medications: The Role of Alternative Weight Maintenance Program
academic.oup.com
To view or add a comment, sign in
-
☣ ☣ PUBLIC HEALTH EMERGENCY: Individuals with obesity are often excluded from clinical trials. ☣ ☣ 🙏🏽 THANKS Courtney Southwick, MS - Health Science Writer for your great article in HealthCentral Corporation. 💡 💡 MY TWO CENTS: WHY? 💊 Researchers might be disincentivized to include patients with obesity in their trials because of how their weight and weight-related health complications could affect the intervention 💊 Obesity is associated with over 200 complications, some of which may disqualify someone from participating in clinical trials. 💊 Weight bias, stigma, and discrimination likely play a big role. Even when individuals with obesity are eligible for a clinical trial, they might not be inclined to participate for a variety of reasons related to their disease. THE DANGER 🚨 This is a huge problem. 🚨 It’s challenging for clinicians to treat patients with obesity with certain medications if we don’t know which dose or frequency to prescribe. 🚨 Standard dosage and titration regimens could lead to underdosing or overdosing individuals with obesity. CALL TO ACTION 🙋🏽♀️ Raising awareness in a variety of ways is important. 🙋🏽♀️ Health care providers need to be armed with inclusive research, or knowledge of research limitations, so we can treat patients as effectively and safely as possible. 🙋🏽♀️ And patients need to be aware of these research limitations so they can advocate for themselves when medications do not seem to be working or when they develop potential side effects. THANK YOU TO ALL OF THE SMART PEOPLE WORKING ON THIS PROBLEM 🌟 Ted Kyle 🌟 Barbara Senich 🌟 Christina Chow, PhD 🌟 Sundar Srinivasan 🌟 Brandon Fremd 🌟 Christopher Bruno 📰 READ the full article here: https://lnkd.in/e9YAt_Ua Emerald Lake Safety - Obesity Action Coalition - The Obesity Society Weill Cornell Medicine - Krystle Lopez #obesity - #publichealth - #safety - #medications
Obese People Are Missing in Many Clinical Trials, Increasing Their Health Risks
healthcentral.com
To view or add a comment, sign in
-
With the evolution of GLP-1s and their unsustainable costs, employers have an opportunity to rethink their weight health benefits and offer solutions that focus on holistic, long-term good health. Transcarent’s new end-to-end Weight Health care experience is grounded in clinical quality, personalization, access and affordability. It is the only cardiometabolic solution on the market that leverages all elements of care delivery on a single platform to drive the biggest ROI for plan sponsors. Transcarent is the One Place for Weight Health. #OnePlaceForHealth
Introducing the One Place for Weight Health from Transcarent. It is the first comprehensive Weight Health care experience that provides self-insured employers affordable access to pharmaceutical treatments alongside lifestyle management, behavioral coaching support and industry-leading surgical care, all on one platform. Each Member has access to an individualized plan designed to meet the needs of their specific weight health journey, informed by analytics, clinical insights, and clinical protocols. The One Place for Health and Care is now the One Place for Weight Health. #OnePlaceForHealth https://lnkd.in/e3vVCNtG
Transcarent Launches One Place for Weight Health – Transcarent
transcarent.com
To view or add a comment, sign in
Professor of Medicine; Head, Unit of Therapeutic Patient Education, University Hospitals of Geneva; Director, WHO Collaborating Centre; Vice-President, Swiss Association for the Study of Metabolic Diseases and Obesity
1moThe missing piece here why the patients stopped GLP-1 analogs is related to the multifactorial origin of obesity as a disease. Medication alone, like surgery alone, could never be enaugh. Medication is just one "complementary" approach which could help only if the people living with obesity are followed by real trained obesity specialists.